135 related articles for article (PubMed ID: 20529879)
21. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis.
Rabbani SA; Valentino ML; Arakelian A; Ali S; Boschelli F
Mol Cancer Ther; 2010 May; 9(5):1147-57. PubMed ID: 20423991
[TBL] [Abstract][Full Text] [Related]
22. HCSGD: An integrated database of human cellular senescence genes.
Dong Q; Han H; Liu X; Wei L; Zhang W; Zhao Z; Zhang MQ; Wang X
J Genet Genomics; 2017 May; 44(5):227-234. PubMed ID: 28529078
[TBL] [Abstract][Full Text] [Related]
23. YAGM: a web tool for mining associated genes in yeast based on diverse biological associations.
Wu WS; Wang CC; Jhou MJ; Wang YC
BMC Syst Biol; 2015; 9 Suppl 6(Suppl 6):S1. PubMed ID: 26678566
[TBL] [Abstract][Full Text] [Related]
24. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
25. PubMeth: a cancer methylation database combining text-mining and expert annotation.
Ongenaert M; Van Neste L; De Meyer T; Menschaert G; Bekaert S; Van Criekinge W
Nucleic Acids Res; 2008 Jan; 36(Database issue):D842-6. PubMed ID: 17932060
[TBL] [Abstract][Full Text] [Related]
26. Bosutinib.
Keller G; Schafhausen P; Brümmendorf TH
Recent Results Cancer Res; 2010; 184():119-27. PubMed ID: 20072835
[TBL] [Abstract][Full Text] [Related]
27. CORUM: the comprehensive resource of mammalian protein complexes--2009.
Ruepp A; Waegele B; Lechner M; Brauner B; Dunger-Kaltenbach I; Fobo G; Frishman G; Montrone C; Mewes HW
Nucleic Acids Res; 2010 Jan; 38(Database issue):D497-501. PubMed ID: 19884131
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
Daud AI; Krishnamurthi SS; Saleh MN; Gitlitz BJ; Borad MJ; Gold PJ; Chiorean EG; Springett GM; Abbas R; Agarwal S; Bardy-Bouxin N; Hsyu PH; Leip E; Turnbull K; Zacharchuk C; Messersmith WA
Clin Cancer Res; 2012 Feb; 18(4):1092-100. PubMed ID: 22179664
[TBL] [Abstract][Full Text] [Related]
29. Mining published lists of cancer related microarray experiments: identification of a gene expression signature having a critical role in cell-cycle control.
Finocchiaro G; Mancuso F; Muller H
BMC Bioinformatics; 2005 Dec; 6 Suppl 4(Suppl 4):S14. PubMed ID: 16351740
[TBL] [Abstract][Full Text] [Related]
30. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.
Rhodes DR; Kalyana-Sundaram S; Mahavisno V; Varambally R; Yu J; Briggs BB; Barrette TR; Anstet MJ; Kincead-Beal C; Kulkarni P; Varambally S; Ghosh D; Chinnaiyan AM
Neoplasia; 2007 Feb; 9(2):166-80. PubMed ID: 17356713
[TBL] [Abstract][Full Text] [Related]
31. Extramedullary Retinal Involvement in Chronic Myeloid Leukemia.
Young JM; Jusufbegovic D
Ophthalmol Retina; 2019 Feb; 3(2):132. PubMed ID: 31014760
[No Abstract] [Full Text] [Related]
32. List of lists-annotated (LOLA): a database for annotation and comparison of published microarray gene lists.
Cahan P; Ahmad AM; Burke H; Fu S; Lai Y; Florea L; Dharker N; Kobrinski T; Kale P; McCaffrey TA
Gene; 2005 Oct; 360(1):78-82. PubMed ID: 16140476
[TBL] [Abstract][Full Text] [Related]
33. [New treatment option for patient with CML-bosutinib].
Takahashi N
Gan To Kagaku Ryoho; 2015 May; 42(5):563-7. PubMed ID: 26054091
[No Abstract] [Full Text] [Related]
34. GeneSigDB--a curated database of gene expression signatures.
Culhane AC; Schwarzl T; Sultana R; Picard KC; Picard SC; Lu TH; Franklin KR; French SJ; Papenhausen G; Correll M; Quackenbush J
Nucleic Acids Res; 2010 Jan; 38(Database issue):D716-25. PubMed ID: 19934259
[TBL] [Abstract][Full Text] [Related]
35. The role of bosutinib in the treatment of chronic myeloid leukemia.
Gambacorti-Passerini C; le Coutre P; Piazza R
Future Oncol; 2020 Jan; 16(2):4395-4408. PubMed ID: 31833784
[TBL] [Abstract][Full Text] [Related]
36. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
[TBL] [Abstract][Full Text] [Related]
37. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
[TBL] [Abstract][Full Text] [Related]
38. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
Keller G; Schafhausen P; Brummendorf TH
Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
[TBL] [Abstract][Full Text] [Related]
39. PINA 3.0: mining cancer interactome.
Du Y; Cai M; Xing X; Ji J; Yang E; Wu J
Nucleic Acids Res; 2021 Jan; 49(D1):D1351-D1357. PubMed ID: 33231689
[TBL] [Abstract][Full Text] [Related]
40. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Hill BG; Kota VK; Khoury HJ
Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
